TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17967134
Drug: Calcium 1
Normalized name: Calcium 10-undecenoate
DrugBank: Calcium undecylenate (DB15678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1 g/d and vitamin D 800 UI/d
Study: 15984982
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg neostigmine
Study: 15984982
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg neostigmine + 0.4 mg glycopyrrolate
Study: 7474041
Drug: 6.9% carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9% carbohydrate-electrolyte solution (CHO)
Study: 1849786
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cisplatin at 70 mg/m2 i.v. on day 1 and etoposide at 100 mg/m2 i.v. on day 1 and 200 mg/m2 orally on days 2 and 3)
Study: 6891844
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cisplatin
Study: 6891844
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of different cytostatic drugs
Study: 6891844
Drug: Modern chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern chemotherapy with cisplatin
Study: 28054322
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/d for 5 days)
Study: 20488830
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g glucose
Study: 20122586
Drug: Landiolol (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.125 mg/kg loading infusion followed by 0.04 mg/kg/min infusion)
Study: 17717930
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with magnesium sulfate
Study: 14586719
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 to 100 mg/day)
Study: 14586719
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 5 mg/day)
Study: 10776007
Drug: 100-mg slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg slow-release aspirin (Disprin CV) daily
Study: 8924063
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg twice daily
Study: 1579511
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral bacteriotherapy using a combination of anaerobe fecal Lactobacilli
Study: 1579511
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral bacteriotherapy using a combination of anaerobe fecal Lactobacilli
Study: 22847373
Drug: Thiopental plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental plus ketamine (0.5 mg/kg)
Study: 16148375
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus enalapril (10‐20 mg/day)
Study: 16148375
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus Accupro (slow titration from 5 to a maximum 20 mg/day)
Study: 16148375
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (glycosides, diuretics, peripheral vasodilators)
Study: 26197707
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg/day
Study: 12115175
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 800 mg/day
Study: 12115175
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 1200 mg/day
Study: 10471564
Drug: Heparin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (10 U/ml)
Study: 10471564
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and Vancomycin (10 U/ml and 25 microg/ml)
Study: 2291418
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplementation (45-90 mg of Zn2+, as zinc sulfate)
Study: 7317899
Drug: Nifedipine 0
Normalized name: nifedipine 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 0 mg
Study: 31504721
Drug: High-sodium, high-cheese
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium, high-cheese intervention (HNaC; 5500 mg/d sodium, 170 g/d cheese)
Study: 31504721
Drug: Low-sodium, high-cheese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium, high-cheese intervention (LNaC; 1500 mg/d sodium, 170 g/d cheese)
Study: 31504721
Drug: High-sodium, no-dairy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium, no-dairy intervention (HNa; 5500 mg/d sodium)
Study: 11274545
Drug: MS-325 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-325 (all doses)
Study: 11274545
Drug: Conventional contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional contrast agent-enhanced angiography
Study: 2463702
Drug: Stable epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable epidural opioid treatment (median dose: 90 mg morphine/24 hours, range 16‐600)
Study: 2463702
Drug: Stable epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable epidural opioid treatment
Study: 2463702
Drug: Epidural opioid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural opioid treatment of neurogenic pain
Study: 2463702
Drug: Epidural opioid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural opioid treatment in low dosage group (less than 300 mg morphine/24 hours)
Study: 2463702
Drug: Epidural opioid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural opioid treatment in high dosage group (equal or greater than 300 mg morphine/24 hours)
Study: 229506
Drug: ACTH-fragment 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH-fragment 4-10 (30 mg SC)
Study: 31099281
Drug: Xiaoaiping (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoaiping (combined with routine chemotherapy)
Study: 31099281
Drug: Routine chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy only (control group)
Study: 12781509
Drug: Antibiotics to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics to reduce the reservoir of infection
Study: 8963479
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ramipril (ramiprilat)
Study: 6261369
Drug: Veralipride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralipride (100 mg/day for 20 days)
Study: 30179573
Drug: 20-week dialectical
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-week dialectical behavior therapy (DBT) skills training group
Study: 30497507
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day of phytosterols and 10 g/day of inulin-enriched soymilk
Study: 22960644
Drug: Active monochromatic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active monochromatic infrared energy (MIRE) therapy
Study: 22960644
Drug: Placebo MIRE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MIRE therapy
Study: 18821708
Drug: Glucosamine 500
Normalized name: glucosamine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine 500 mg 3 times daily
Study: 18821708
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 400 mg 3 times daily
Study: 12388930
Drug: Colostrinin® (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrinin® (100 μg of PRP complex) taken every other day for three weeks, followed by a 2-week hiatus, for a total of 16 months (or 28 months for 13 patients).
Study: 12388930
Drug: Colostrinin® (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrinin® (100 μg of PRP complex)
Study: 1971540
Drug: beta 1-blockade
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta 1-blockade (atenolol, 50 mg, administered two times)
Study: 1971540
Drug: beta 2-blockade
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta 2-blockade (ICI 118,551, 50 mg, administered three times)
Study: 7026038
Drug: Heparin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1,000 units/ml) injected intraarterially at a dosage of 0.1 mg/kg prior to catheter removal
Study: 7026038
Drug: Placebo injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected intraarterially at a dosage of 0.1 mg/kg prior to catheter removal
Study: 7026038
Drug: Heparin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1,000 units/ml)
Study: 30601417
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg 1 day before surgery and for 6 weeks after surgery)
Study: 22710021
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin
Study: 21464051
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no statin/low-dose statin)
Study: 18832244
Drug: Maraviroc once
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc once daily
Study: 18832244
Drug: Maraviroc twice
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc twice daily
Study: 16750963
Drug: Regular non-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular non-aspirin NSAID use
Study: 1536472
Drug: Pentoxifylline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (2 x 600 mg oral per day)
Study: 23638711
Drug: Prenatal 60
Normalized name: ARDISIA CRENATA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal 60 mg iron and folate combined with UHM
Study: 20702514
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy for 20 weeks
Study: 20702514
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment with disconnected magnetotherapy equipment for 20 weeks
Study: 30986791
Drug: RotaTeq vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RotaTeq vaccine
Study: 17117100
Drug: Topical betacaine
Normalized name: Butacaine
DrugBank: Butacaine (DB11502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betacaine application
Study: 17117100
Drug: Topical betacaine
Normalized name: Butacaine
DrugBank: Butacaine (DB11502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betacaine followed by skin cooling
Study: 15265098
Drug: Helping during
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Helping during treatment
Study: 11933878
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of steroids (oral or intramuscular dexamethasone, 0.6 mg/kg)
Study: 11933878
Drug: Steroids in
Normalized name: Other antiinflammatory and antirheumatic agents, non-steroids in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids in pharyngitis
Study: 11933878
Drug: Single-dose and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose and short-term steroid therapy (less than a week)
Study: 11933878
Drug: Routine use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine use of steroids for recurrent ENT infections
Study: 9640129
Drug: Sulphasalazine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine therapy
Study: 1093427
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 10 mg diazepam
Study: 1093427
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection into the thigh of 10 mg diazepam
Study: 1093427
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection into the buttock of 10 mg diazepam
Study: 1093427
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and thigh routes of administration
Study: 27992949
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing for phenprocoumon in younger patients (< 75 years)
Study: 27992949
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing for phenprocoumon in older patients (≥ 75 years)
Study: 27992949
Drug: Acenocoumarol users
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol users with genotype-guided dosing
Study: 25971907
Drug: Obatoclax (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obatoclax (20 mg/m2) in combination with fludarabine and rituximab (FR)
Study: 17658633
Drug: Bosentan (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.)
Study: 17053955
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for 8 weeks
Study: 14689888
Drug: DBTC catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBTC catheter (transurethral perfusion and drainage with antibiotics)
Study: 6143042
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated cold‐adapted reassortant influenza virus vaccine (10(7.5) TCID50, intranasally)
Study: 6143042
Drug: Inactivated vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccine (administered intramuscularly)
Study: 6143042
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated cold‐adapted reassortant influenza virus vaccine (10(7.5) TCID50)
Study: 6143042
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated cold‐adapted reassortant influenza virus vaccine
Study: 27752167
Drug: CHOPE+L-asparaginase (L-ASP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOPE+L-asparaginase (L-ASP) regimen
Study: 27752167
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival rates in CHOPE+L
Study: 22041866
Drug: mIL‐11 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mIL‐11 (7.5 μg/kg/day) for 10 days, beginning 72 h after chemotherapy (cycle-1)
Study: 22041866
Drug: rhIL‐11 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL‐11 (25 μg/kg/day) for 10 days (cycle-2)
Study: 20215823
Drug: Antibiotics (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (Group 1)
Study: 20215823
Drug: EPS-Antibiotics (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPS-Antibiotics (Group 4)
Study: 17661724
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Aurene, 600 mg)
Study: 17661724
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Trileptal, 600 mg)
Study: 16160416
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Study: 16160416
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Study: 16160416
Drug: 0.8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Study: 1824143
Drug: Sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1 g 4 times a day (Group 1)
Study: 1824143
Drug: Famotidine, 40
Normalized name: Famotidine, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine, 40 mg single evening dose (Group 2)
Study: 6242957
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg bid
Study: 29601316
Drug: Diazoxide (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (200-400 mg daily, twice a day)
Study: 25771490
Drug: Capsaicin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (5 mg/d)
Study: 24725805
Drug: Oral α‐methyl‐para‐tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral α‐methyl‐para‐tyrosine (AMPT)
Study: 22295812
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of acupuncture and medicine (heat-producing needling at Pishu (BL 20) and Zhishi (BL 52) with Terazosin Hydrochloride, Bisoprolol Fumarate tablets, or compound Reserpinum Triamterene tablet for high blood pressure)
Study: 22295812
Drug: Medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine group I (Renin‐Angiotensin‐Aldosterone system interruption with Benazepril Hydrochloride and Telmisartan for blood pressure control)
Study: 22295812
Drug: Medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine group II (placebo with same medicine therapy as combined therapy for high blood pressure)
Study: 17703390
Drug: Sedato-analgesic cocktail
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedato-analgesic cocktail (midazolam, ketamine, pentazocine plus propofol) (Group B)
Study: 12394941
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of human serum albumin every 8 hrs with continuous infusion furosemide
Study: 10337446
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort extract LoHyp-57 (800 mg daily)
Study: 1780996
Drug: Ivermectin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (100 micrograms/kg, single dose)
Study: 1780996
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) (3 mg/kg for one day, then 6 mg/kg daily for 12 d)
Study: 7174860
Drug: Metoclopramide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (40 mg)
Study: 7174860
Drug: Metoclopramide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (60 mg)
Study: 8842603
Drug: Glimepiride 4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 4 mg
Study: 20300631
Drug: Local standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local standard of care (immunological and clinical criteria for treatment failure, discretionary VL testing)
Study: 11926713
Drug: Flurbiprofen 8.75
Normalized name: flurbiprofen 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75 mg lozenge with concomitant antibiotics
Study: 8082521
Drug: Ultralente insulin
Normalized name: ultralente insulin, beef
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralente insulin (Humulin U)
Study: 8082521
Drug: Intermediate insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate insulin (Humulin I)
Study: 2554837
Drug: Pindolol 15
Normalized name: pindolol 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 15 mg/day (beta-blocker)
Study: 27055279
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion (0.26 μg/kg/h)
Study: 27055279
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion (2.0 μg/kg/h)
Study: 25151916
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (PE plus sertraline)
Study: 20348496
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg primaquine daily for 7 days
Study: 20348496
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg primaquine daily for 7 days
Study: 9011483
Drug: Two years
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two years of IFN therapy
Study: 9011483
Drug: Continuing IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing IFN therapy for at least 12 months
Study: 9011483
Drug: Initial IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial IFN treatment courses of 24 months
Study: 7961557
Drug: Clozapine concentration
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine concentration > 420 ng/mL
Study: 7961557
Drug: Clozapine concentration
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine concentration < 420 ng/mL
Study: 7961557
Drug: Clozapine concentration
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine concentration > 420 ng/mL at Week 12
Study: 7961557
Drug: Clozapine concentration
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine concentration < 420 ng/mL at Week 12
Study: 26771267
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone (0.5 mg/kg in 5 mL saline)
Study: 26771267
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 mL IV saline)
Study: 21755811
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops)